Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28027921 | 0.78 | GRM4 (0.32) | — | |
| SCHEMBL8633571 | 0.74 | MEN1 (0.41) | MGLLMEN1KMT2ACA12CA1 | |
| Lithium Ion SCHEMBL8633570 | 0.72 | MEN1 (0.39) | MGLLMEN1KMT2ACA12CA1 | |
| SCHEMBL8633596 | 0.69 | ALDH1A1 (0.44) | MEN1KMT2A | |
| SCHEMBL10663417 | 0.68 | GAA (0.40) | MEN1KMT2A | |
| SCHEMBL2348912 | 0.68 | LAP3 (0.37) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL4812637 | 0.66 | CYP19A1 (0.46) | MGLLMEN1KMT2ACA12CA1 | |
| SCHEMBL4184332 | 0.66 | KDM4C (0.47) | MEN1KMT2A | |
| SCHEMBL11258174 | 0.65 | KDM4C (0.46) | MEN1KMT2A | |
| SCHEMBL31204399 | 0.64 | MEN1 (0.47) | MGLLMEN1KMT2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110218177-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218177-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | CETP, SLCO2B1, OXA1L | MGLL 1277/4885FDPS 642/4885MEN1 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.